Truist Financial Corp Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Truist Financial Corp decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 59.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 168,411 shares of the medical research company's stock after selling 242,657 shares during the quarter. Truist Financial Corp owned about 0.09% of IQVIA worth $33,094,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Smith Group Asset Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at about $1,616,000. Simplify Asset Management Inc. grew its position in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after buying an additional 3,894 shares during the period. Nordea Investment Management AB grew its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $941,000. Finally, Fifth Third Bancorp boosted its stake in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. UBS Group decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $251.22.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company's stock.

IQVIA Trading Down 1.3 %

IQV traded down $2.51 during midday trading on Thursday, hitting $194.01. The company's stock had a trading volume of 1,081,192 shares, compared to its average volume of 1,402,682. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a 50-day moving average price of $199.86 and a two-hundred day moving average price of $216.95. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $34.16 billion, a P/E ratio of 25.87, a PEG ratio of 1.98 and a beta of 1.48.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.86 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.